在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

CD47 (Magrolimab) Recombinant Monoclonal Antibody

  • 中文名稱:
    CD47 Recombinant Monoclonal Antibody
  • 貨號:
    CSB-RA004940MA1HU
  • 規格:
    ¥1320
  • 圖片:
    • The Binding Activity of Human CD47 with Anti-CD47 recombinant antibody
      Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CD47 (CSB-MP004940HUd7) at 2 μg/mL can bind Anti-CD47 recombinant antibody. The EC50 is 1.343-1.561 ng/mL.
    • Untransfected CT26 cells (green line) and transfected Human DLL3 & CD47 CT26 stable cells (red line) were stained with anti-CD47 antibody (CSB-RA004940MA1HU) (2μg/1*106cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
    • Untransfected CT26 cells (green line) and transfected Human DLL3 & CD47 CT26 stable cells (red line) were stained with anti-DLL3 antibody (CSB-RA882142MA2HU) (2μg/1*106cells), washed and then followed by APC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
  • 其他:

產品詳情

  • 產品描述:
    CD47重組單克隆抗體(CSB-RA004940MA1HU)是針對免疫檢查點分子CD47研發的高特異性檢測工具。CD47作為廣泛表達的跨膜蛋白,通過結合巨噬細胞表面SIRPα受體傳遞"別吃我"信號,在腫瘤免疫逃逸、紅細胞穩態及神經突觸重塑中發揮關鍵調控作用。本抗體經嚴格驗證適用于酶聯免疫吸附實驗(ELISA)及流式細胞術(FC),在流式檢測中推薦使用1:50至1:200稀釋度,可精準識別天然構象的CD47抗原表位,其高親和力特性確保在復雜樣本中仍能保持穩定的檢測性能。該產品適用于體外研究CD47在腫瘤微環境中的表達調控、免疫細胞互作機制解析以及相關信號通路研究,為探索腫瘤免疫治療策略、血液系統疾病模型構建及神經退行性疾病的分子機制提供可靠工具。尤其適用于細胞表面標志物檢測、免疫細胞功能分析等實驗體系,滿足科研工作者在基礎研究和轉化醫學研究中的多樣化需求。
  • Uniprot No.:
  • 基因名:
  • 別名:
    Antigen identified by monoclonal antibody 1D8 antibody; Antigenic surface determinant protein OA3 antibody; CD 47 antibody; CD47 antibody; CD47 antigen (Rh-related antigen; integrin-associated signal transducer) antibody; CD47 antigen antibody; CD47 glycoprotein antibody; CD47 molecule antibody; CD47_HUMAN antibody; IAP antibody; Integrin Associated Protein antibody; Integrin associated signal transducer antibody; Integrin-associated protein antibody; Leukocyte surface antigen CD47 antibody; MER 6 antibody; MER6 antibody; OA 3 antibody; OA3 antibody; OTTHUMP00000041152 antibody; OTTHUMP00000041153 antibody; Protein MER6 antibody; Rh related antigen antibody; Surface antigen identified by monoclonal antibody 1D8 antibody; Magrolimab
  • 反應種屬:
    Human
  • 免疫原:
    Recombinant Human CD47 protein
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    hIgG1
  • 純化方式:
    Affinity-chromatography
  • 克隆號:
    4E5
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA, FC
  • 推薦稀釋比:
    Application Recommended Dilution
    FC 1:50-1:200
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.
  • 基因功能參考文獻:
    1. results suggest that cancers can evolve SE to drive CD47 overexpression to escape immune surveillance PMID: 28378740
    2. overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection. PMID: 28968355
    3. High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
    4. CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity. PMID: 25914268
    5. Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level. PMID: 29042481
    6. CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC. PMID: 27411490
    7. Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1). PMID: 28393401
    8. Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers. PMID: 27863402
    9. High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma. PMID: 28801364
    10. TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors. PMID: 27856600
    11. this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade. PMID: 28077173
    12. we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control. PMID: 28100392
    13. In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction. PMID: 27742621
    14. thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation/self-renewal. PMID: 27259369
    15. Engineering macrophages to eat cancer: from "marker of self" CD47 and phagocytosis to differentiation PMID: 28522599
    16. the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading. PMID: 27349907
    17. Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation. PMID: 28076333
    18. Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages/M2 were independently related to shorter survivals. PMID: 27322955
    19. Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts. PMID: 27232934
    20. CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms PMID: 26446381
    21. CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure. PMID: 27714815
    22. The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development. PMID: 27855370
    23. Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors. PMID: 26840086
    24. suggest that microglial activation may be partially caused by CD47/signal regulatory protein-alpha- and CD200/CD200R-mediated reductions in the immune inhibitory pathways PMID: 27095555
    25. Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy. PMID: 27091975
    26. Data suggest a reduction in the CD47 antigen/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs). PMID: 26573233
    27. atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis' PMID: 27437576
    28. CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor. PMID: 26093091
    29. agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo PMID: 26116271
    30. CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer. PMID: 26077800
    31. study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis PMID: 25593301
    32. CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1. PMID: 26512116
    33. CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas. PMID: 25717063
    34. CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury PMID: 26311851
    35. CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells. PMID: 25747479
    36. Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages. PMID: 26085683
    37. While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not PMID: 25943033
    38. Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis PMID: 25837251
    39. during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation PMID: 25896326
    40. Report poor prognosis/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47. PMID: 25230070
    41. Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively. PMID: 24840181
    42. The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells. PMID: 24887393
    43. expression is induced following EBV infection of B cells; ligation cases G1 arres PMID: 24911792
    44. CD47 regulates the epigenetic code by targeting UHRF1. PMID: 25550546
    45. Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells. PMID: 25001859
    46. the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47 PMID: 24848268
    47. CD47 associates with and regulates VEGFR2 in T cells. CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation. PMID: 25200950
    48. Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS/PAR2 signaling. PMID: 24523067
    49. CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL. PMID: 24726056
    50. Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells. PMID: 24006483

    顯示更多

    收起更多

  • 亞細胞定位:
    Cell membrane; Multi-pass membrane protein.
  • 組織特異性:
    Very broadly distributed on normal adult tissues, as well as ovarian tumors, being especially abundant in some epithelia and the brain.
  • 數據庫鏈接:

    HGNC: 1682

    OMIM: 601028

    KEGG: hsa:961

    STRING: 9606.ENSP00000355361

    UniGene: Hs.446414



主站蜘蛛池模板: 亚洲精品99久久久久中文字幕| 伊人久久大香线蕉av一区| 日本真人做爰免费的视频| 国产乱子伦视频在线播放| 99久久国产自偷自偷免费一区| 欧美日韩精品suv| 无码人妻少妇久久中文字幕蜜桃 | 久久精品国产亚洲夜色av网站| 久久久久久国产精品mv| 小12箩利洗澡无码视频网站| 久久婷婷大香萑太香蕉av人| 亚洲国产成人久久综合同性 | 人妻av中文字幕无码专区| 无码一区二区| 欧美大屁股xxxxhd黑色| 国内精品视这里只有精品| 欧美老妇bbbwwbbbww| 成 人 a v免费视频在线观看 | 国产午夜不卡片免费视频| 亚洲精品国产精品乱码不卡√| 黑人巨茎大战白人美女| 性欧美老人牲交xxxxx视频| 国产乱子伦三级在线播放| 宅男午夜成年影视在线观看| 亚洲va中文字幕无码一二三区| 亚洲人成网站在小说| 麻豆av一区二区三区| 国产精品三级在线观看无码| 亚洲国产av导航第一福利网| 玩弄了裸睡少妇人妻野战| 超清制服丝袜无码av福利网| 很黄很黄的曰批视频| 国产日韩成人内射视频| 国产麻豆剧传媒精品av| 亚洲精品国产福利一区二区| 一色屋精品视频在线观看免费 | 热re99久久6国产精品免费| 999久久久免费精品国产| 又爽又黄又无遮挡的视频| 日本三级理论久久人妻电影| 午夜成人无码片在线观看影院|